Equities

Urogen Pharma Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Urogen Pharma Ltd

Actions
  • Price (EUR)18.10
  • Today's Change-0.20 / -1.09%
  • Shares traded200.00
  • 1 Year change+81.00%
  • Beta1.3435
Data delayed at least 15 minutes, as of Feb 20 2026 11:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments237137100
Total Receivables, Net201513
Total Inventory9.235.674.33
Prepaid expenses8.851011
Other current assets, total1.080.820.81
Total current assets276169129
Property, plant & equipment, net3.792.363.75
Goodwill, net------
Intangibles, net------
Long term investments5.024.500
Note receivable - long term------
Other long term assets0.592.042.74
Total assets286178136
LIABILITIES
Accounts payable116.515.53
Accrued expenses282216
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.75----
Other current liabilities, total6.423.042.34
Total current liabilities463124
Total long term debt1239998
Total debt1249998
Deferred income tax------
Minority interest------
Other liabilities, total125114104
Total liabilities295244225
SHAREHOLDERS EQUITY
Common stock0.120.090.06
Additional paid-in capital797614488
Retained earnings (accumulated deficit)(806)(679)(577)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.060.01(0.11)
Total equity(8.8)(65)(89)
Total liabilities & shareholders' equity286178136
Total common shares outstanding423223
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.